Table 1

Characteristics of the included clinical trials in the study
Study Study design Telbivudine/Control (n) HBeAg (+) (-) (n) Baseline ALT (U/L) HBV DNA level(log copies/ml) Treatment Newborn immunization
Telbivudine Control Telbivudine Control Telbivudine Control Lower enrollment limit Telbivudine (mg/d) Control HBIG (IU) HVB ac (mg)
Zhang 2009 [19] RCT 31/30 NA NA NA NA Mean (SD): 7.38 (0.81)

Mean (SD):

7,460 (0.45

7 600 from 28-32 wk of gestation to 1 mo after delivery No treatment 200 at birth and 30 d 10 at 0, 1, 6 mo
Zhao 2010 [22] RCT 30/30 30/0 30/0 Normal (NA) Normal (NA) Positive (NA) Positive (NA) Positive (NA) 600 from 28 wk of gestation to 1 mo after delivery No treatment 200 at birth and 30 d 10 at 0, 1, 6 mo
Zeng 2010 [20] NRCT 22/26 22/0 26/0 Normal NA) Normal (NA) Mean (SD): 7.66 (0.82) Mean (SD): 7.13 (1.29) 5 600 from 28 wk of gestation to delivery No treatment 200 at birth 10 at 0, 1, 6 mo
Zhang 2010 [21] NRCY 60/60 60/0 60/0 NA NA Mean (SD): 7.66 (0.82) Mean (SD): 6.86 (6,10) 6 600 from 28 wk of gestation to 1 mo after delivery No treatment 200 at birth and 30 d 10 at 0, 1, 6 mo
Yao 2011 [23] NRCT 28/30 NA NA Mean (SD): 93.6 (226.8) Mean (SD): 50.5 (5.5) Mean (SD): 7.50 (0.60) Mean (SD): 7.50 (0.70) 6 600 fro 28 wk of getation to wk after delivery No treatment 200 at birth 10 at 0, 1, 6H
Han 2011 [5] NRCT 135/94 135/0 94/0 Mean (SD): 35.67 (43.41 Mean (SD): 42.53 (40.13) Mean (SD): 8.10 (0.56) Mean (SD): 7.98 (0.61) 7 600 from 20-32 wk of gestation to 1 mo after delivery No treatment 200 at birth and 15 d 20 at 0, 1, 6,

RCT: randomized controlled trial; NRCT: non randomized controlled trial: NA: not available; Mean (SD): mean (standard deviation): HBGIG: hepatitis B immunoglobulin; IU: International Unit; HBVac: hepatitis B vaccine.

Deng et al.

Deng et al. Virology Journal 2012 9:185   doi:10.1186/1743-422X-9-185

Open Data